Real‐world persistence and dose titration of <scp>GLP</scp> ‐1 receptor agonists in type 2 diabetes: A <scp>UK</scp> population‐based cohort study by obesity and cardiovascular disease status
In UK primary care, GLP-1RA persistence was suboptimal and dose escalation was frequently delayed across all patient stratifications, including individuals with established CVD.
Authors
- NICOLA NAPOLI
- Andrea M. Burden (ORCID: https://orcid.org/0000-0001-7082-8530)
- Morten Frost Nielsen
- Franziska Sophie Ulrich
Institutions
- Università Campus Bio-Medico (IT)
- Washington University in St. Louis (US)
- Odense University Hospital (DK)
- University of Alabama at Birmingham (US)
- ETH Zurich (CH)
- Campus Bio Medico University Hospital (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1111/dom.70535
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 30.73
Funders
- Novartis Foundation
- Novartis Stiftung für Medizinisch-Biologische Forschung